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plant	DSA.	However,	 antibody-mediated	 rejection	of	 renal	 allografts	





Non-HLA	 antibodies	 have	 been	 described	 against	 a	 variety	 of	
targets,	but	 large-scale	 studies	 incorporating	analysis	of	 these	an-
tibodies	 simultaneously	 to	assess	 their	 clinical	 relevance	 in	kidney	
transplantation	are	lacking.	In	this	retrospective	study	on	a	large	na-
tional	 cohort	of	4770	 renal	 transplant	 recipients,	we	assessed	 the	
impact	on	graft	survival	of	IgG	autoantibodies	against	14	previously	
identified	target	proteins.11
2  | MATERIAL S AND METHODS
2.1 | Study population
Between	 January	 1995	 and	 December	 2005,	 6097	 kidney	 trans-
plantations	 with	 a	 negative	 complement-dependent	 cytotoxicity	
crossmatch	were	performed	in	The	Netherlands.	Clinical	data	were	
obtained	from	the	Dutch	Organ	Transplant	Registry.	The	use	of	sera	
and	 experimental	 protocols	 was	 approved	 by	 the	 Research	 Ethics	
Committee	 for	Biobanks	and	 the	Medical	Ethics	Committee	of	 the	










2.2 | Assessment of non‐HLA antibodies
We	 selected	 14	 non-HLA	 target	 proteins	 from	 the	 literature.11 
Antibodies	 against	 the	 glomerular	 basement	 membrane	 pro-
tein	 agrin	 have	 been	 described	 in	 the	 context	 of	 transplant	
glomerulopathy.12	 Antibodies	 against	 adipocyte	 plasma	 mem-
brane-associated	 protein	 (APMAP),	 Rho	 GDP-dissociation	 in-
hibitor	 2	 (ARHGDIB),	 Rho	 guanine	 nucleotide	 exchange	 factor	
6	 (ARHGEF6),	 Lamin	B1,	BPI	 fold-containing	 family	B	member	1	
(LPLUNC1),	protein	kinase	C	zeta	type	(PRKCZ),	and	tubulin	beta-
4B	(Tubb4B)	were	all	demonstrated	either	in	chronic	hemodialysis	
patients	 or	 patients	 awaiting	 kidney	 transplantation.	 Antibodies	





allograft	 failure.13,14	 Pre-	 and	 posttransplant	 endorepellin	 anti-
body	 levels	were	 increased	 in	 patients	with	 vascular	 rejection15 
and	 phospholipase	 A2	 receptor	 (PLA2R)	 antibodies	 are	 strongly	
associated	 with	 primary	 membranous	 nephropathy.16	 We	 com-










rectly	 coupled	proteins	 (transferrin	 and	14	 target	 proteins),	 13	 in-
house	produced	HaloTag-coupled	proteins	(transferrin	and	12	target	














labeled	 polymer	 anti-rabbit	 Ig	 detection	 antibody	 (BrightVision,	
VWR,	Duiven).	Bound	antibody	was	visualized	with	Nova	Red	sub-








(HRs)	 and	95%	 confidence	 intervals	 (95%	CIs)	were	 derived	 using	
multivariable	Cox	regression.	A	Bonferroni	correction	was	used	to	
adjust	for	multiple	comparisons	when	studying	the	effects	of	non-
HLA	antibodies	on	graft	 survival	 and	P	 <	 .002	 (.05	divided	by	25	
non-HLA	antibodies)	was	considered	as	statistically	significant	(ap-
plied	for	analyses	in	Tables	1,	S3,	and	S4).	We	adjusted	in	both	the	
AKME	and	Cox	 regression	 for	 recipient	age	 (quadratic)	and	donor	
age	 (quadratic),	 cold	 ischemia	 time	 (for	donation	after	brain	death	
or	 cardiac	 death),	 years	 on	 dialysis	 (quadratic),	 induction	 therapy	
TA B L E  1  Multivariable	analyses	of	the	effect	of	antibodies	against	ARHGDIB	on	10-year	death-censored	graft	failure
 
No. (%) of transplantations 
with anti‐ARHGDIB antibodies Hazard ratio 95% CI P‐value
Total	cohort	(N	=	4770) 134	(2.8) 1.701 1.265-2.288 .0004
Deceased	donors	(N	=	3276) 94	(2.9) 1.820 1.318-2.531 .0003





against	HLA-A/B/DR/DQ.	CI,	confidence	interval.	A	Bonferroni	correction	was	used	to	adjust	for	multiple	comparisons	with	P < .002 considered as 
statistically	significant.








3.1 | Determination of a clinically relevant cut‐off 
for the presence of non‐HLA antibodies
We	 analyzed	 the	 4770	 pretransplant	 sera	 using	 our	multiplex	 non-
























3.2 | Impact of pretransplant non‐HLA antibodies 
on long‐term graft survival





of	 the	 other	 non-HLA	 antibodies	 on	 10-year	 graft	 survival	 of	 the	
total	cohort	is	summarized	in	Table	S2.
Because	our	cohort	contained	a	 relatively	high	proportion	of	
living	 donors	 and	 we	 previously	 found	 that	 DSA	 had	 mainly	 an	
impact	 on	 deceased-donor	 transplantations	 with	 only	 a	 limited	
effect	on	living-donor	transplantations,19	we	also	analyzed	the	im-
pact	of	non-HLA	antibodies	on	long-term	graft	survival	according	
to	 donor	 status	 (3276	 deceased-donor	 and	 1494	 living-donor	
transplantations).	 After	 deceased-donor	 transplantation,	 the	
AKME	according	to	the	presence	of	ARHGDIB	antibodies	showed	
a	10-year	death-censored	graft	survival	of	61%	(95%	CI	50%-70%)	










the	 patient,	 donor,	 and	 transplant	 characteristics	 between	 the	







graft	 failure	 after	 transplantation	with	 a	 deceased-donor	 kidney	
(Table	1,	HR	1.82,	95%	CI	1.32-2.53,	P	=	 .0003).	At	1	year	after	
transplantation,	 the	HR	was	1.620	 (95%	CI,	0.993-2.643)	 for	 the	
anti-ARHGDIB-positive	 group	 compared	 to	 the	 anti-ARHGDIB-
negative	group	(Table	S3).	Furthermore,	the	rejection-free	survival	
was	comparable	for	patients	with	and	without	antibodies	against	
ARHGDIB	 (Figure	S3).	 For	 the	 living-donor	 transplantations,	 the	
presence	 of	 ARHGDIB	 antibodies	 was	 not	 associated	 with	 de-




same	model.	The	hazard	 ratio	 for	a	 living	donor	was	0.563	 (95%	




3.3 | ARHGDIB expression in the kidney
Finally,	 we	were	wondering	where	 in	 the	 kidney	 ARHGDIB	 is	 ex-
pressed.	 Therefore,	 we	 stained	 biopsies	 of	 a	 transplanted	 kidney	








illaries,	 and	 endothelial	 cells	 of	 glomerular	 capillaries.	 In	 addition,	
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ure	 and	 the	 presence	 of	 pretransplant	 non-HLA	 antibodies	 in	 the	
sera	of	4770	kidney	transplantations	performed	in	The	Netherlands	
between	1995	and	2006.	The	results	indicate	that	pretransplant	an-
tibodies	 against	ARHGDIB	 represent	 a	 risk	 factor	 for	 graft	 loss	 in	
deceased-donor	transplantations.
The	 14	 non-HLA	 target	 proteins	 included	 in	 our	 assay	 were	
selected	based	on	 reported	antibody	 specificity	 in	kidney	 trans-
plant	patients	or	patients	with	end-stage	renal	disease,	and	their	
expression	 in	 the	 kidney.	 A	 number	 of	 these	 non-HLA	 antibod-
ies	 have	 been	 examined	 in	 relation	 to	 kidney	 transplantation.	
Antibodies	against	AT1R	were	associated	with	rejection	and	graft	




and	 with	 more	 severe	 vascular	 rejection.21	 Antibodies	 against	
LG3,	 a	 C-terminal	 fragment	 of	 perlecan,	 were	 associated	 with	
acute	tubulointerstitial	rejection	and	long-term	renal	allograft	dys-
function.15,22	 Antibodies	 against	 PLA2R,	 LPLUNC,	 APMAP,	 and	
PRKCZ	were	 described	 previously	 in	 small	 case-series	 and	 have	




ysis.	 In	general,	non-HLA	antibodies	 frequently	occur	within	 the	








antibody,	 optimally	 discriminating	 patients	 with	 long-term	 func-
tioning	grafts	vs	graft	loss,	we	did	not	find	associations	between	














presence	 of	 anti-ARHGDIB	 antibodies	 and	 ischemia	 reperfusion	
injury,	which	 is	 less	 prominent	 in	 living-donor	 kidney	 transplanta-
tion.27	ARHGDIB	 is	widely	expressed,	 including	 in	 the	 renal	pelvis	
and	glomeruli.	Increased	expression	of	ARHGDIB	has	been	reported	
in	several	 solid	 tumors	and	hematological	malignancies.28-31	Bilalic	
et al32	 first	 described	 that	 dialysis	 patients	 can	 have	 autoreactive	
antibodies	 against	 ARHGDIB.	 Further	 analysis	 in	 kidney	 biopsies	
showed	 cytoplasmic	 expression	 in	 endothelial	 cells	 of	 interlobular	



















46.9	±	14.1 47.9	±	13.4 .462a 46.1	±	14.1




6.8	±	18.7 9.2	±	25.1 .574a 6.9	±	18.9
Highest	PRA	(%,	
mean	±	SD)
16.4	±	28.2 15.4	±	30.4 .300a 16.4	±	28.2
Dialysis,	n	(%)   .455b  
No 147	(4.6) 3	(3.0)  150	(4.6)
Yes	–	hemodialysis 1853	(58.2) 49	(52.1)  1902	(58.1)
Yes – peritoneal 
dialysis
1164	(36.6) 41	(43.6)  1205	(36.8)
Unknown 18	(0.6) 1	(1.1)  19	(0.6)
Time	on	dialysis	(y,	
mean	±	SD)
3.4	±	2.6 3.4	±	2.2 .814a 3.4	±	2.6
Donor     
Donor	age	(y,	
mean	±	SD)
42.7	±	16.0 46.0	±	14.6 .062a 42.8	±	16.0
Donor	female	sex	–	
no.	(%)
1489	(46.8) 46	(48.9) .681b 1535	(46.9)
Cold-ischemia	time	
(hours,	mean	±	SD)
21.8	±	7.2 23.5	±	7.7 .043a 21.8	±	7.2
Transplant     
Repeat transplantation 
–	no.	(%)




423	(13.3) 10	(10.6) .454b 433	(13.2)
Induction	therapy     
IL-2	receptor	blocker	
–	no.	(%)	
651	(20.5) 14	(14.9) .186b 665	(20.3)
T-cell	depleting	
antibodyc	no.	(%)
134	(4.2) 0	(0) .042b 134	(4.1)
Initial	immunosuppres-
sion	–	no.	(%)
    
Steroids 3120	(98.1) 90	(95.7) .117b 3210	(98.0)
MMF/azathioprine 2377	(74.7) 63	(67.0) .092b 244	(74.4)
Cyclosporine/
tacrolimus
3000	(94.3) 88	(93.6) .785b 3088	(94.3)
Sirolimus 171	(5.4) 9	(9.6) .078b 180	(5.4)
Other 417	(13.1) 11	(11.7) .691b 428	(13.1)
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arteries	and	peritubular	capillaries,	and	 in	podocytes.	We	consider	
it	possible	that	cellular	damage	caused	by	ischemia	reperfusion	re-
sults	 in	accessibility	of	ARHGDIB	 in	endothelial	cells	 to	circulating	
auto-antibodies.	After	binding,	anti-ARHGDIB	antibodies	may	initi-
ate	 complement	 activation	 causing	 local	 inflammation,	which	may	










non-HLA	 antibodies	 in	 patient	 groups.	 Because	 there	 are	 no	 com-
mercially	available	reference	sera	against	the	non-HLA	antibodies	we	
selected,	we	were	not	 able	 to	properly	 compare	our	 Luminex	assay	
to	 other	 commercially	 available	 ELISA	 or	 Luminex	 autoantibody	 as-
says.	In	the	sera	used	in	our	multiplex	assay,	we	measured	non-HLA	
IgG	antibodies.	 It	 is	possible	that	some	non-HLA	antibodies	relevant	































In	 conclusion,	 our	 study	 demonstrates	 that	 pretransplant	 non-
HLA	antibodies	against	ARHGDIB	are	a	significant	risk	factor	in	de-
ceased-donor	transplantation.	These	antibodies	occur	independently	
from	DSA	or	other	non-HLA	antibodies	 investigated.	 It	 is	 currently	
unknown	whether	 the	presence	of	 these	antibodies	 is	a	biomarker,	
as	 is	 the	 case	 in	many	 autoimmune	diseases,	 or	whether	 they	play	
a	 role	 in	 the	 pathogenesis	 of	 graft	 loss.	Although	 validation	 of	 our	
findings	in	independent	cohorts	is	necessary,	based	on	these	results,	
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